DOCSLIB.ORG

Reference List Concerning Anosmia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reference List Concerning Anosmia ANOSMIA RMA ID Reference List for RMA366-2 as at December 2020 Number Access Medicine (2008). Refractory asthma. 17th Edition, Vol 2: 1606. 61372 Retrieved 27 July 2011, from http://accessmedicine.com/popup.aspx?aID=2861712&print=yes_chapter Ackerman BH, Kasbekar N (1997). Disturbances of taste and smell 61111 induced by drugs. Pharmacotherapy, 17(3): 482-96. Adams DR, Ajmani GS, Pun VC, et al (2016). Nitrogen dioxide pollution 56103 exposure is associated with olfactory dysfunction in older U.S. adults. Int Forum Allergy Rhinol, 6(12): 1245-52. Adler CH, Connor DJ, Hentz JG, et al (2010). Incidental Lewy body 59585 disease: clinical comparison to a control cohort. Mov Disord, 25(5): 642- 6. Adler CH, Gwinn KA, Newman S (1998). Olfactory function in restless 5802 legs syndrome. Mov Disord, 13(3): 563-5. Aguirre-Mardones C, Iranzo A, Vilas D, et al (2015). Prevalence and 35454 timeline of nonmotor symptoms in idiopathic rapid eye movement sleep behavior disorder. J Neurol, 262(6): 1568-78. Ahman M, Holmstrom M, Kolmodin-Hedman B, et al (2001). Nasal 96364 symptoms and pathophysiology in farmers. Int Arch Occup Environ Health, 74(4): 279-84. Ajmani GS, Suh HH, Pinto JM (2017). Effects of ambient air pollution 5815 exposure on olfaction: A review. Environ Health Perspect, 124(11): 1683- 93. Ajmani GS, Suh HH, Wroblewski KE, et al (2016). Fine particulate matter 83088 exposure and olfactory dysfunction among urban-dwelling older US adults. Environ Res, 151: 797-803. Ajmani GS, Suh HH, Wroblewski KE, et al (2017). Smoking and olfactory 81237 dysfunction: a systematic literature review and meta-analysis. Laryngoscope, 127(8): 1753-61. Aksoy C, Elsurer C, Artac H, et al (2018). Evaluation of olfactory function 81168 in children with seasonal allergic rhinitis and its correlation with acoustic rhinometry. Int J Pediatr Otorhinolaryngol, 113: 188-91. Akyol L, Gunbey E, Karli R, et al (2016). Evaluation of olfactory function 96365 in Behcet’s disease. Eur J Rheumatol, 3(4): 153-6. AlBader A, Levine CG, Casiano RR (2017). Does endoscopic sinus 42366 surgery improve olfaction in nasal polyposis? Laryngoscope, 127(10): 2203-4. Alosco ML, Jarnagin J, Tripodis Y, et al (2017). Olfactory function and 45156 associated clinical correlates in former National Football League players. J Neurotrauma, 34(4): 772-80. Altman KW, Desai SC, Moline J, et al (2011). Odor identification ability 96366 and self-reported upper respiratory symptoms in workers at the post-9/11 World Trade Center site. Int Arch Occup Environ Health, 84(2): 131-7. Page 1 of 26 Altungdag A, Ay SA, Hira S, et al (2017). Olfactory and gustatory 96367 functions in patients with non-complicated type 1 diabetes mellitus. Eur Arch Otorhinolaryngol, 274(6): 2621-7. Alvarez P, Papaseit E, Perez V, et al (2019). Reversible taste and smell 96368 dysfunction associated with sodium valproate and quetiapine in bipolar depression: a case report. Actas Esp Psiquiatr, 47(1): 33-6. Alvarez-Camacho M, Gonella S, Campbell S, et al (2017). A systematic 96369 review of smell alterations after radiotherapy for head and neck cancer. Cancer Treat Rev, 54: 110-21. Alves A, Martins C, Delgado L, et al (2010). Exercise-induced rhinitis in 96370 competitive swimmers. Am J Rhinol Allergy, 24(5): e114-7. American Medical Association (2002). Criteria for Rating Impairments of 61391 the Cranial Nerves. Guides to the Evaluation of Permanent Impairment, 5th Edition, Chapter 13.4: 327. American Medical Association, Chicago. Amezaga J, Alfaro B, Rios Y, et al (2018). Assessing taste and smell 96371 alterations in cancer patients undergoing chemotherapy according to treatment. Support Care Cancer, 26(12): 4077-86. Amital H, Agmon-Levin A, Shoenfeld N, et al (2014). Olfactory 44756 impairment in patients with the fibromyalgia syndrome and systemic sclerosis. Immunol Res, 60(2-3): 201-7. Anderson DM, Keith J, Novak PD (Lexicographers) (2003). Dorland's 41430 Illustrated Medical Dictionary, 30th Edition, WB Saunders, Philadelphia. Anderson DM, Keith J, Novak PD (Lexicographers) (2003). Pellagra. 61387 Dorland's Illustrated Medical Dictionary, 30th Edition, 1391. WB Saunders, Philadelphia. Anosmia Foundation of Canada (2003). Causes of Anosmia. Retrieved 61363 27 July 2011, from http://www.anosmiafoundation.com/causes.shtml Antunes MB, Bowler R, Doty RL (2007). San Francisco/Oakland Bay 60696 Bridge Welder Study: olfactory function. Neurology, 69(12): 1278-84. Applegate LM. Louis ED (2005). Essential tremor: Mild olfactory 89530 dysfunction in a cerebellar disorder. Parkinsonism Relat Disord, 11(6): 399-402. Arcot Jayagopal L, von Geldern G (2018). Anosmia as the initial 96372 presentation of neurosarcoidosis. Neurology, 91(22): 1020-1. Arnold C (2019). Sensory overload? Air pollution and impaired olfaction. 96373 Environ Health Perspect, 127(6): 62001. Asai H, Udaka F, Hirano M, et al (2008). Odour abnormalities caused by 61394 bilateral thalamic infarction. Clin Neurol Neurosurg, 110(5): 500-1. Asal N, Bayar Muluk N, Inal M, et al (2018). Olfactory bulbus volume and 96374 olfactory sulcus depth in psychotic patients and patients with anxiety disorder/depression. Eur Arch Otorhinolaryngol, 275(12): 3017-24. Atalar AC, Erdal Y, Tekin B, et al (2018). Olfactory dysfunction in multiple 20452 sclerosis. Mult Scler Relat Disord, 21: 92-6. Aubart FC, Ouayoun M, Brauner M, et al (2017). Sinonasal involvement 52170 in sarcoidosis: A case-control study of 20 patients. Medicine (Baltimore), 85(6): 365-71. Aydin E, Tekeli H, Karabacak E, et al (2016). Olfactory functions in 5827 patients with psoriasis vulgaris: correlations with the severity of the disease. Arch Dermatol Res, 308(6): 409-14. Bakker K, Catroppa C, Anderson V (2014). Olfactory dysfunction in 20467 pediatric traumatic brain injury: a systematic review. J Neurotrauma, 31(4): 308-14. Barnett R, Maruff P, Purcell R, et al (1999). Impairment of olfactory 59711 identification in obsessive-compulsive disorder. Psychol Med, 29(5): 1227-33. Bar-Sela S, Levy M, Westin JB, et al (1992). Medical findings in nickel- 59818 cadmium battery workers. Isr J Med Sci, 28(8-9): 578-83. Page 2 of 26 Bauer LO, Mott AE (1996). Differential effects of cocaine, alcohol, and 96375 nicotine dependence on olfactory evoked potentials. Drug Alcohol Depend, 42(1): 21-6. Baum ED, Boudousquie AC, Li S, et al (1998). Sarcoidosis with nasal 59790 obstruction and septal perforation. Ear Nose Throat J, 77(11): 896-8, 900-2. Bayard S, Plazzi G, Poli F, et al (2010). Olfactory dysfunction in 5831 narcolepsy with cataplexy. Sleep Med, 11(9): 876-81. Beard MD, Mackay-Sim A (1987). Loss of sense of smell in adult, 61395 hypothyroid mice. Brain Res, 433(2): 181-9. Becker S, Pflugbeil C, Groger M, et al (2012). Olfactory dysfunction in 96376 seasonal and perennial allergic rhinitis. Acta Otolaryngol, 132(7): 763-8. Benjamin E, Pickles J (1997). Chlorine-induced anosmia. A case 59796 presentation. J Laryngol Otol, 111(11): 1075-6. Berlit P (1992). Clinical and laboratory findings with giant cell arteritis. J 59803 Neurol Sci, 111(1): 1-12. Bernhardson BM, Tishelman C, Rutqvist LE (2009). Olfactory changes 59667 among patients receiving chemotherapy. Eur J Oncol Nurs, 13(1): 9-15. Bersani G, Quartini A, Ratti F, et al (2013). Olfactory identification deficits and associated response inhibition in obsessive-compulsive disorder: on 96377 the scent of the orbitofronto-striatal model. Psychiatry Res, 210(1): 208- 14. Besser G, Erlacher B, Aydinkoc-Tuzcu K, et al (2020). Body-mass-index associated differences in ortho-and retronasal olfactory function and the 95175 individual significance of olfaction in health and disease. J Clin Med, 9(2): 366. Binder DK, Horton JC, Lawton MT, et al (2004). Idiopathic intracranial 61396 hypertension. Neurosurgery, 54(3): 538-51; discussion 551-2. Blackburn GL (2009). [Comment] Counteracting the effects of 59800 chemosensory dysfunction. J Support Oncol, 7(2): 66-7. Comment on ID: 59799. Blanco S, Sanroman L, Perez-Calvo S, et al (2019). Olfactory and 95387 cognitive functioning in patients with fibromyalgia. Psychol Health Med, 24(5): 530-41. Boerner B, Tini GM, Fachinger P, et al (2017). Significant improvement of olfactory performance in sleep apnea patients after three months of nasal 96378 CPAP therapy - Observational study and randomized trial. PLoS One, 12(2): e017087. Boesveldt S, Postma EM, Boak D, et al (2017). Anosmia-A critical review. 95176 Chem Senses, 42(7): 513-23. Bolla KI, Schwartz BS, Stewart W, et al (1995). Comparison of neurobehavioral function in workers exposed to a mixture of organic and 32177 inorganic lead and in workers exposed to solvents. Am J Ind Med, 27(2): 231-46. Bombini MF, Peres FA, Lapa AT, et al (2018). Olfactory function in 95177 systemic lupus erythematosus and systemic sclerosis. A longitudinal study and review of the literature. Autoimmun Rev, 17(4): 405-12. Bonfils P, Avan P, Faulcon P, et al (2005). Distorted odorant perception: 96379 Analysis of a series of 56 patients with parosmia. Arch Otolaryngol Head Neck Surg, 131(2): 107-12. Bonfils P, Malinvaud D, Soundry Y, et al (2009). Surgical therapy and 61365 olfactory function. B-ENT, 5(Suppl 13): 77-87. [Abstract] Bor AS, Niemansburg SL, Wermer MJ, et al (2009). Anosmia after coiling 59586 of ruptured aneurysms: Prevalence, prognosis, and risk factors. Stroke, 40(6): 2226-8. Page 3 of 26 Bougault V, Turmel J, Boulet LP (2010). Effect of intense swimming 96380 training on rhinitis in high-level competitive swimmers. Clin Exp Allergy, 40(8): 1238-46. Bramerson A, Johansson L, Ek L, et al (2004). Prevalence of olfactory 96381 dysfunction: The Skovde population-based study. Laryngoscope, 114(4): 733-7. Bramerson A, Nyman J, Nordin S, et al (2013). Olfactory loss after head 96382 and neck cancer radiation therapy. Rhinology, 51(3): 206-9. Bratt M, Skandsen T, Hummel T, et al (2018).
Load more

Recommended publications
  • Second Edition
    COVID-19 Evidence Update COVID-19 Update from SAHMRI, Health Translation SA and the Commission on Excellence and Innovation in Health Updated 4 May 2020 – 2nd Edition “What is the prevalence, positive predictive value, negative predictive value, sensitivity and specificity of anosmia in the diagnosis of COVID-19?” Executive Summary There is widespread reporting of a potential link between anosmia (loss of smell) and ageusia (loss of taste) and SARS-COV-2 infection, as an early sign and with sudden onset predominantly without nasal obstruction. There are calls for anosmia and ageusia to be recognised as symptoms for COVID-19. Since the 1st edition of this briefing (25 March 2020), there has been a significant expansion of literature on this topic, including 3 systematic reviews. Predictive value: The reported prevalence of anosmia/hyposmia and ageusia/hypogeusia in SARS-COV-2 positive patients are in the order of 36-68% and 33-71% respectively. There are reports of anosmia as the first symptom in some patients. Estimates from one study for hyposmia and hypogeusia: • Positive likelihood ratios: 4.5 and 5.8 • Sensitivity: 46% and 62% • Specificity: 90% and 89% The US Centres for Disease Control and Prevention (CDC) has added new loss or taste or smell to its list of recognised symptoms for SARS-COV-2 infection. To date, the World Health Organization has not. Conclusion: There is sufficient evidence to warrant adding loss of taste and smell to the list of symptoms for COVID-19 and promoting this information to the public. Context • Early detection of COVID-19 is key to the ongoing management of the pandemic.
    [Show full text]
  • Taste and Smell Disorders in Clinical Neurology
    TASTE AND SMELL DISORDERS IN CLINICAL NEUROLOGY OUTLINE A. Anatomy and Physiology of the Taste and Smell System B. Quantifying Chemosensory Disturbances C. Common Neurological and Medical Disorders causing Primary Smell Impairment with Secondary Loss of Food Flavors a. Post Traumatic Anosmia b. Medications (prescribed & over the counter) c. Alcohol Abuse d. Neurodegenerative Disorders e. Multiple Sclerosis f. Migraine g. Chronic Medical Disorders (liver and kidney disease, thyroid deficiency, Diabetes). D. Common Neurological and Medical Disorders Causing a Primary Taste disorder with usually Normal Olfactory Function. a. Medications (prescribed and over the counter), b. Toxins (smoking and Radiation Treatments) c. Chronic medical Disorders ( Liver and Kidney Disease, Hypothyroidism, GERD, Diabetes,) d. Neurological Disorders( Bell’s Palsy, Stroke, MS,) e. Intubation during an emergency or for general anesthesia. E. Abnormal Smells and Tastes (Dysosmia and Dysgeusia): Diagnosis and Treatment F. Morbidity of Smell and Taste Impairment. G. Treatment of Smell and Taste Impairment (Education, Counseling ,Changes in Food Preparation) H. Role of Smell Testing in the Diagnosis of Neurodegenerative Disorders 1 BACKGROUND Disorders of taste and smell play a very important role in many neurological conditions such as; head trauma, facial and trigeminal nerve impairment, and many neurodegenerative disorders such as Alzheimer’s, Parkinson Disorders, Lewy Body Disease and Frontal Temporal Dementia. Impaired smell and taste impairs quality of life such as loss of food enjoyment, weight loss or weight gain, decreased appetite and safety concerns such as inability to smell smoke, gas, spoiled food and one’s body odor. Dysosmia and Dysgeusia are very unpleasant disorders that often accompany smell and taste impairments.
    [Show full text]
  • Clinical Diagnosis and Treatment of Olfactory Dysfunction
    Clinical Diagnosis and Treatment of Olfactory Dysfunction Seok Hyun Cho Hanyang Med Rev 2014;34:107-115 http://dx.doi.org/10.7599/hmr.2014.34.3.107 Department of Otorhinolaryngology-Head and Neck Surgery, Hanyang University College of Medicine, Seoul, Korea pISSN 1738-429X eISSN 2234-4446 Olfactory dysfunction is a relatively common disorder that is often under-recognized by Correspondence to: Seok Hyun Cho Department of Otorhinolaryngology-Head both patients and clinicians. It occurs more frequently in older ages and men, and decreases and Neck Surgery, Hanyang University patients’ quality of life, as olfactory dysfunction may affect the emotion and memory func- Hospital, 222 Wangsimni-ro, Seongdong-gu, tions. Three main causes of olfactory dysfunction are sinonasal diseases, upper respiratory Seoul 133-792, Korea Tel: +82-2-2290-8583 viral infection, and head trauma. Olfactory dysfunction is classified quantitatively (hypos- Fax: +82-2-2293-3335 mia and anosmia) and qualitatively (parosmia and phantosmia). From a pathophysiologi- E-mail: [email protected] cal perspective, olfactory dysfunction is also classified by conductive or sensorineural types. All patients with olfactory dysfunction will need a complete history and physical examina- Received 17 April 2014 Revised 23 June 2014 tion to identify any possible or underlying causes and psychophysical olfactory tests are Accepted 3 July 2014 essential to estimate the residual olfactory function, which is the most important prognos- This is an Open Access article distributed under tic factor. CT or MRI may be adjunctively used in some indicated cases such as head trauma the terms of the Creative Commons Attribution and neurodegenerative disorders.
    [Show full text]
  • Both Anxiety and Joint Laxity Determine the Olfactory Features in Panic Disorder
    Psychiatry Research xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Psychiatry Research journal homepage: www.elsevier.com/locate/psychres Both anxiety and joint laxity determine the olfactory features in panic disorder ⁎ Emma Buróna, , Antonio Bulbenaa,b, Andrea Bulbena-Cabréa,c, Sílvia Rosadob, Guillem Pailhezb a Autonomous University of Barcelona, Department of Psychiatry and Forensic Medicine (UAB), Bellaterra, Spain b Mar Health Park, Neuropsychiatry and Drug Addiction Institute (INAD), Barcelona, Spain c Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA ARTICLE INFO ABSTRACT Keywords: Previous research showed a high sensitivity in sensorial modalities in panic disorder (PD). This disorder has been Panic disorder consistently associated to the joint hypermobility syndrome (JHS). In non-clinical samples, this collagen al- Olfactory threshold teration has been also related to an enhanced sensitivity in some sensorial modalities. The main aim of this study Smell reactivity is to explore the olfactory functioning in PD in relation to JHS. Sixty patients with PD and sixty healthy controls Olfactory awareness performed the Sniffin’ Sticks Test (SST) (threshold subtest), and completed the Affective Impact of Odors scale Joint hypermobility syndrome (AIO), the Relational Scale of Olfaction (EROL), and the Odor Awareness Scale (OAS). Clinical symptom rating scales and JHS assessment were also obtained. PD patients showed enhanced odor acuity, greater reactivity to smells and also increased odor awareness compared to the healthy controls. Within the patients group, those suffering from JHS displayed higher functioning in all olfactory domains compared to the non-JHS ones. The JHS and anxiety measures emerged as predictor variables of the olfactory function.
    [Show full text]
  • Neuropsychiatric Manifestations of COVID-19 Can Be Clustered in Three
    www.nature.com/scientificreports OPEN Neuropsychiatric manifestations of COVID‑19 can be clustered in three distinct symptom categories Fatemeh Sadat Mirfazeli1,8, Atiye Sarabi‑Jamab2,8, Amin Jahanbakhshi3, Alireza Kordi4, Parisa Javadnia4, Seyed Vahid Shariat1, Oldooz Aloosh5, Mostafa Almasi‑Dooghaee6 & Seyed Hamid Reza Faiz7* Several studies have reported clinical manifestations of the new coronavirus disease. However, few studies have systematically evaluated the neuropsychiatric complications of COVID‑19. We reviewed the medical records of 201 patients with confrmed COVID‑19 (52 outpatients and 149 inpatients) that were treated in a large referral center in Tehran, Iran from March 2019 to May 2020. We used clustering approach to categorize clinical symptoms. One hundred and ffty‑one patients showed at least one neuropsychiatric symptom. Limb force reductions, headache followed by anosmia, hypogeusia were among the most common neuropsychiatric symptoms in COVID‑19 patients. Hierarchical clustering analysis showed that neuropsychiatric symptoms group together in three distinct groups: anosmia and hypogeusia; dizziness, headache, and limb force reduction; photophobia, mental state change, hallucination, vision and speech problem, seizure, stroke, and balance disturbance. Three non‑ neuropsychiatric cluster of symptoms included diarrhea and nausea; cough and dyspnea; and fever and weakness. Neuropsychiatric presentations are very prevalent and heterogeneous in patients with coronavirus 2 infection and these heterogeneous presentations may be originating from diferent underlying mechanisms. Anosmia and hypogeusia seem to be distinct from more general constitutional‑like and more specifc neuropsychiatric symptoms. Skeletal muscular manifestations might be a constitutional or a neuropsychiatric symptom. In December 2019 a number of severe acute respiratory syndrome (SARS) were reported in Wuhan, China that became eventually a pandemic infection with over 8 million reported cases until June 2020 1.
    [Show full text]
  • Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: 3 Prevalence, Severity, Timing and Associated Characteristics 4 5 Marlene M
    Complete Manuscript Click here to access/download;Complete Manuscript;manuscript 042220 v3.docx This manuscript has been accepted for publication in Otolaryngology-Head and Neck Surgery. 2 Olfactory dysfunction and sinonasal symptomatology in COVID-19: 3 prevalence, severity, timing and associated characteristics 4 5 Marlene M. Speth, MD, MA1, Thirza Singer-Cornelius, MD1, Michael Obere, PhD2, Isabelle 6 Gengler, MD3, Steffi J. Brockmeier, MD1, Ahmad R. Sedaghat, MD, PhD3 7 8 9 1Klinik für Hals-, Nasen-, Ohren- Krankheiten, Hals-und Gesichtschirurgie, Kantonsspital 10 Aarau, Switzerland, 2Institute for Laboratory Medicine, Kantonsspital Aarau, Aarau, 11 Switzerland, 3Department of Otolaryngology—Head and Neck Surgery, University of 12 Cincinnati College of Medicine, Cincinnati, OH, USA. 13 14 15 Funding: MMS and TSC received funding from Kantonsspital Aarau, Department of 16 Otolaryngology, Funded by Research Council KSA 1410.000.128 17 18 Conflicts of Interest: None 19 20 21 Authors’ contributions: 22 MMS: designed and performed study, wrote and revised manuscript, approved final 23 manuscript. 24 TSC: designed and performed study, approved final manuscript. 25 MO: performed study, approved final manuscript. 26 IG: designed study, revised manuscript and approved final manuscript 27 SJB: designed and performed study, revised manuscript and approved final manuscript 28 ARS: conceived, designed and performed study, wrote and revised manuscript, approved 29 final manuscript. 30 31 32 Corresponding Author: 33 Ahmad R. Sedaghat, MD, PhD 34
    [Show full text]
  • Topamax® Tablets and Sprinkle Capsules Topiramate New Zealand Data Sheet
    TOPAMAX® TABLETS AND SPRINKLE CAPSULES TOPIRAMATE NEW ZEALAND DATA SHEET 1. PRODUCT NAME TOPAMAX® 25 mg, 50 mg, 100 mg & 200 mg film-coated tablets TOPAMAX® Sprinkle 15 mg, 25 mg & 50 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION TABLETS Each tablet contains 25 mg, 50 mg, 100 mg or 200 mg of topiramate. Excipient(s) with known effect: Lactose monohydrate For a full list of excipients, see section 6.1. SPRINKLE CAPSULES Each capsule contains 15 mg, 25 mg or 50 mg of topiramate. Excipients with known effect: Sugar For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM TABLETS 25 mg: Round, white, film-coated tablets, marked “TOP” on one side and “25” on the other. 50 mg: Round, light-yellow, film-coated tablets, marked “TOP” on one side and “50” on the other 100 mg: Round, yellow, film-coated tablets, marked “TOP” on one side and “100” on the other 200 mg: Round, salmon, film-coated tablets, marked “TOP” on one side and “200” on the other. SPRINKLE CAPSULES Hard capsules enclosing small, white to off-white spheres. Each gelatin capsule consists of a clear (natural) capsule cap and a white capsule body. 15 mg: imprinted with “TOP” on cap and “15 mg” on body 25 mg: imprinted with “TOP” on cap and “25 mg” on body 50mg: imprinted with “TOP” on cap and “50mg” on body (not marketed). CCDS201005v23 1 TOPAMAX(201215)ADS 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS EPILEPSY TOPAMAX is indicated in adults and children, 2 years and over: • as monotherapy in patients with newly diagnosed epilepsy • for conversion to monotherapy in patients with epilepsy • as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome.
    [Show full text]
  • Association of Olfactory and Pulmonary Function in Middle-Aged and Older Adults: the Korea National Health and Nutrition Examination Survey
    Journal of Clinical Medicine Article Association of Olfactory and Pulmonary Function in Middle-Aged and Older Adults: The Korea National Health and Nutrition Examination Survey Ji-Sun Kim , Jun-Ook Park, Dong-Hyun Lee , Ki-Hong Chang and Byung Guk Kim * Department of Otolaryngology-Head and Neck Surgery, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea; [email protected] (J.-S.K.); [email protected] (J.-O.P.); [email protected] (D.-H.L.); [email protected] (K.-H.C.) * Correspondence: [email protected]; Tel.: +82-2-2030-4558 Abstract: Objectives: To identify the relationship between pulmonary function and subjective olfac- tory dysfunction in middle-aged and older adults. Materials and Methods: We used Korea National Health and Nutrition Examination Survey data from 2010 to 2012 to analyze 6191 participants in their 50s or older. Results: The frequency of olfactory dysfunction was 6.8% among the subjects with normal pulmonary function tests, but was significantly more frequent in those diagnosed with restrictive (9.6%) or obstructive (10.1%) pulmonary function. Forced volume vital capacity, forced expiratory volume (FEV)1, FEV6, and peak expiratory flow were significantly lower in the olfactory dysfunction group. The risk of olfactory dysfunction was significantly associated with obstructive pulmonary function (odds ratio (OR) [95% confidence interval (CI)]: 1.449 [1.010–2.081]) after ad- justing for confounders (sex, rhinitis, chronic rhinosinusitis, hypertension, dyslipidemia, education Citation: Kim, J.-S.; Park, J.-O.; Lee, D.-H.; Chang, K.-H.; Kim, B.G. level, stress, depressed mood, and suicidal ideation).
    [Show full text]
  • Depression, Olfaction, and Quality of Life: a Mutual Relationship
    brain sciences Review Depression, Olfaction, and Quality of Life: A Mutual Relationship Marion Rochet 1, Wissam El-Hage 1,2 ID , Sami Richa 3, François Kazour 1,4 ID and Boriana Atanasova 1,* ID 1 UMR 1253, iBrain, Université de Tours, Inserm, 37200 Tours, France; [email protected] (M.R.); [email protected] (W.E.-H.); [email protected] (F.K.) 2 CHRU de Tours, Clinique Psychiatrique Universitaire, 37044 Tours, France 3 Department of Psychiatry, Faculty of Medicine, Saint-Joseph University, P.O. Box 17-5208, 11-5076 Beirut, Lebanon; [email protected] 4 Psychiatric Hospital of the Cross, 60096 Jal Eddib, Lebanon * Correspondence: [email protected]; Tel.: +33-2-47-36-73-05 Received: 13 April 2018; Accepted: 3 May 2018; Published: 4 May 2018 Abstract: Olfactory dysfunction has been well studied in depression. Common brain areas are involved in depression and in the olfactory process, suggesting that olfactory impairments may constitute potential markers of this disorder. Olfactory markers of depression can be either state (present only in symptomatic phases) or trait (persistent after symptomatic remission) markers. This study presents the etiology of depression, the anatomical links between olfaction and depression, and a literature review of different olfactory markers of depression. Several studies have also shown that olfactory impairment affects the quality of life and that olfactory disorders can affect daily life and may be lead to depression. Thus, this study discusses the links between olfactory processing, depression, and quality of life. Finally, olfaction is an innovative research field that may constitute a new therapeutic tool for the treatment of depression.
    [Show full text]
  • COVID-19 Anosmia Reporting Tool: Initial Findings
    Complete Manuscript Click here to access/download;Complete Manuscript;CART v1.7.docx This manuscript was accepted for publication by Otolaryngology-Head and Neck Surgery. 1 1 COVID-19 Anosmia Reporting Tool: Initial Findings 2 3 Rachel Kaye, MD, Rutgers New Jersey Medical School, Newark, NJ 4 5 C.W. David Chang, MD, FACS, University of Missouri School of Medicine, Columbia, 6 MO 7 (ORCID 0000-0002-0141-7583) 8 One Hospital Dr, MA 314, Columbia, MO 65212 9 615.414.5932 10 [email protected] 11 12 Ken Kazahaya, MD, MBA, FACS, Children’s Hospital of Philadelphia, Philadelphia, PA 13 14 Jean Brereton, MBA, American Academy of Otolaryngology—Head and Neck Surgery 15 Foundation, Alexandria, Virginia, USA 16 17 James C. Denneny III, MD, FACS, Johns Hopkins School of Medicine, Baltimore, MD 18 19 Keywords: Coronavirus; COVID-19; anosmia; dysgeusia; smell; taste This manuscript was accepted for publication by Otolaryngology-Head and Neck Surgery. This manuscript was accepted for publication by Otolaryngology-Head and Neck Surgery. 2 20 Abstract 21 There is accumulating anecdotal evidence that anosmia and dysgeusia are associated 22 with the COVID-19 pandemic. In order to investigate their relationship to SARS-CoV2 23 infection, the American Academy of Otolaryngology–Head and Neck Surgery (AAO- 24 HNS) developed the COVID-19 Anosmia Reporting Tool for Clinicians for the basis of 25 this pilot study. This tool allows healthcare providers to confidentially submit cases of 26 anosmia and dysgeusia related to COVID-19. We analyzed the first 237 entries which 27 revealed that anosmia was noted in 73% of subjects prior to COVID-19 diagnosis and 28 was the initial symptom in 26.6%.
    [Show full text]
  • 124 Epochs of Anosmia and Ageusia in Multiple Sclerosis
    78 ABSTRACTS 2 Director, Head of Corporate Medical Affairs, H. 29.0 for patients with anxious distress in the adjunctive Lundbeck A/S, Valby, Denmark brexpiprazole (n = 462) group and 29.1 in the placebo 3 Director, Global Medical Affairs, Otsuka (n = 327) group; while those with anxious depression Pharmaceutical Development & Commercialization, were 28.9 (brexpiprazole; n = 384) and 28.6 (placebo; Inc., Princeton, NJ, USA n = 282). Compared to those receiving placebo, patients 4 Senior Director, Biostatistics, Otsuka Pharmaceutical with both anxious distress and anxious depression who Development & Commercialization, Inc., Princeton, received adjunctive brexpiprazole showed a greater NJ, USA 5 Senior Director, Global Medical Affairs, Otsuka improvement in MADRS total score (LS mean difference = = Pharmaceutical Development & Commercialization, -2.38, p 0.0001 and -1.68, p 0.012, respectively). Inc., Princeton, NJ, USA These improvements, compared to placebo, were similar to those in patients who had not met the criteria for ABSTRACT: Study objectives: Symptoms of anxiety are anxious distress (-1.40, p = 0.023) or anxious depression prevalent in Major Depressive Disorder (MDD) and are (-2.17, p < 0.001). associated with greater illness severity, suicidality, impaired functioning and poor response to antidepres- CONCLUSION: Adjunctive brexpiprazole may be effica- sant treatment (ADT). In MDD, anxiety symptoms can be cious in reducing depressive symptoms both in patients assessed as ‘anxious distress’ (new DSM-5 specifier) or with or without symptoms of anxiety. ‘anxious depression’ (score ≥7 on the HAM-D anxiety/ FUNDING ACKNOWLEDGEMENTS: The studies were funded somatization factor). Brexpiprazole is a serotonin– by H. Lundbeck A/S and Otsuka Pharmaceutical Devel- dopamine activity modulator that is a partial agonist at opment & Commercialization, Inc.
    [Show full text]
  • Anosmia but Not Ageusia As a COVID-19-Related Symptom Among Cancer Patients—First Results from the PAPESCO-19 Cohort Study
    cancers Article Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study Ke Zhou 1,*, Audrey Blanc-Lapierre 2, Valérie Seegers 2, Michèle Boisdron-Celle 3, Frédéric Bigot 4, Marianne Bourdon 1,5, Hakim Mahammedi 6, Aurélien Lambert 7 , Mario Campone 8, Thierry Conroy 7 , Frédérique Penault-Llorca 9, Martine M. Bellanger 1,10 and Jean-Luc Raoul 8 1 Department of Human and Social Sciences, Institut de Cancérologie de l’Ouest (ICO), 44805 Saint-Herblain, France; [email protected] (M.B.); [email protected] (M.M.B.) 2 Department of Biostatistic, Institut de Cancérologie de l’Ouest, 44805 Saint-Herblain, France; [email protected] (A.B.-L.); [email protected] (V.S.) 3 Department of Biopathology, Institut de Cancérologie de l’Ouest, 49055 Angers, France; [email protected] 4 Department of Medical Oncology, Institut de Cancérologie de l’Ouest, 49055 Angers, France; [email protected] 5 Research Unit UMR INSERM 1246 SPHERE, Universités de Nantes et Tours, 44035 Nantes, France 6 Department of Medical Oncology, Centre Jean Perrin, 63011 Clermont-Ferrand, France; [email protected] 7 Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54511 Vandoeuvre-lès-Nancy, France; Citation: Zhou, K.; Blanc-Lapierre, [email protected] (A.L.); [email protected] (T.C.) A.; Seegers, V.; Boisdron-Celle, M.; 8 Department of Medical Oncology, Institut de Cancérologie de l’Ouest, 44805 Saint-Herblain, France; Bigot, F.; Bourdon, M.; Mahammedi, [email protected] (M.C.); [email protected] (J.-L.R.) H.; Lambert, A.; Campone, M.; 9 Department of Biopathology and INSERM U1240, Centre Jean Perrin, 63011 Clermont-Ferrand, France; Conroy, T.; et al.
    [Show full text]